MTC S1
Alternative Names: MTC-S1Latest Information Update: 21 Aug 2023
At a glance
- Originator Biotts; National Center for Research and Development
- Developer Biotts
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 21 Aug 2023 Preclinical trials in Type 2 diabetes mellitus (Adjunctive treatment) in Poland (Transdermal) before August 2023 (Biotts pipeline, August 2023)
- 15 Sep 2022 Early research in Type 2 diabetes mellitus (Adjunctive treatment) in Poland (Transdermal) (Biotts pipeline, September 2022)
- 15 Sep 2022 Biotts plans for a preclinical study of MTC S1 in Type 2 diabetes mellitus (Transdermal) (Biotts pipeline, September 2022)